Central Bank & Trust CO Contrafect Corp Transaction History

Central Bank & Trust CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 18, 2023	SELL	$0.09 - $0.19 $1,027 - $2,169	-11,420 Reduced 90.24%	1,235 $0
Q3 2022 Oct 20, 2022	BUY	$0.18 - $3.51 $279 - $5,458	1,555 Added 14.01%	12,655 $2,000
Q2 2022 Jul 22, 2022	BUY	$2.79 - $4.45 $18,414 - $29,370	6,600 Added 146.67%	11,100 $34,000
Q4 2021 Jan 18, 2022	BUY	$2.47 - $4.14 $4,940 - $8,280	2,000 Added 80.0%	4,500 $12,000
Q3 2021 Oct 19, 2021	BUY	$3.19 - $4.43 $7,975 - $11,075	2,500 New	2,500 $10,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Central Bank & Trust CO, based on Form 13F filings with the SEC.

Stay updated on Central Bank & Trust CO with notifications on news.